Synthesis and Cerebrovascular Anti-Ischemic Activity of New 5-Hydroxyadamantan-2-One Derivatives


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

New 5-hydroxyadamantan-2-one derivatives with heteroaromatic, aromatic, and aliphatic acids (nicotinic, succinic, p-chlorophenoxyacetic, 3,4,5-trimethoxybenzoic, and anisic) were synthesized. Their pharmacological properties were studied to discover compounds with cerebrovascular anti-ischemic activity and without hypotensive activity. Esters of succinic acid and 5-hydroxyadamantan-2-one (diester Ia and monoester Ib, 100 mg/kg, i.v.) exhibited the most potent effect on cerebral circulation under ischemic conditions. They did not lower arterial blood pressure. The monoester was less toxic with LD50 740.0 (676.0 – 804.0) mg/kg. Analysis of the cerebrovascular effects of the succinate esters of 5-hydroxyadamantan-2-one using bicuculline revealed a GABA-ergic mechanism of action on cerebral vessels. However, radioligand analysis in vitro using the specific ligand [3H]-SR 95531 found that these esters did not compete for rat-brain membrane GABAA-receptors. Thus, the monoester of succinic acid and 5-hydroxyadamantan-2-one possessed pronounced cerebrovascular anti-ischemic activity and did not produce hypotensive effects. The latter circumstance differentiated it from well-known drugs used in neurology (picamilon, Mexidol, nimodipine, cinnarizine, and Cavinton).

About the authors

E. V. Kurza

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

N. I. Avdyunina

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

T. S. Gan’shina

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

D. V. Maslennikov

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

A. I. Turilova

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

B. M. Pyatin

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

L. N. Grushevskaya

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

N. M. Zaitseva

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

R. F. Bol’shakova

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

G. I. Kovalev

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

E. V. Vasil’eva

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

R. S. Mirzoyan

V. V. Zakusov State Institute of Pharmacology, Russian Academy of Medical Sciences

Email: chem@folium.ru
Russian Federation, 8 Baltiiskaya St., Moscow, 125315

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2018 Springer Science+Business Media, LLC, part of Springer Nature